Market Research Logo

Conference Documentation: Pain Therapeutics

Conference Documentation: Pain Therapeutics

As billions of people globally suffer from pain, it has become a huge problem, with the value of the pharmaceutical market for pain relief reflecting this worldwide epidemic. As a result, new research techniques and drugs are urgently required for a range of chronic pain syndromes.

Returning for its 15th year SMi, are proud to present the UK’s premier event, the 15th Annual Pain Therapeutics Conference, 18th – 19th May 2015, London, UK. Through a series of interactive presentations and panel discussions, this event will give you access to key industry leaders, spotlighting principles and illustrative examples on current activities and trends in clinical and pre-clinical evidence-based and best-practice-based pain medicine. Highlighting research and developments in the field of pain relief this is an event that you will not want to miss!

Key topics include:

The continuing role of opiods in treating chronic pain
Chronic pain as a reversible brain problem
Neurostimulation and its positive impact on the quality of their lives
Animal models and pain – what is new?
Pain and biomarkers"


Day 1
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Anthony Jones, Professor of Neuro-Rheumatology, Human Pain Research Group, University of Manchester
9:10
Chronic pain as a reversible brain problem
Anthony Jones, Professor of Neuro-Rheumatology, Human Pain Research Group, University of Manchester
9:50
The continuing role of opioids in treating chronic pain
Remigiusz Lecybyl, Consultant in Chronic Pain, University Hospital Lewisham
10:30
Morning Coffee
10:50
Recent developments in opioids
Alexander Oksche, Exec Director European Pharmacol Intelligence, Mundipharma
11:30
Pain and biomarkers : ROUNDTABLE DISCUSSION
Richard Knowles, CEO, Knowles Consulting
12:10
Networking Lunch
13:10
Validation of a multimodal nociceptive test battery for early phase clinical drug studies
Dr. Geert Jan Groeneveld, Research Director Neurology & Pain, CNS Department, Centre for Human Drug Research
13:50
Stem cell derived sensory neurons as a model for human pain sensing neurons and a valuable tool for drug discovery
Gareth Young, Senior Scientist, Pfizer Neusentis
14:30
Novel approaches in early clinical development of compounds in neuropathic pain
Dr. Johan A. den Boer, Psychiatrist Director Scientific Affairs & Professor of Psychopharmacology and Neuroscience , PRA Health Sciences
15:10
Afternoon Tea
15:30
Latest advances in the pathophysiology of fibromyalgia
Jordi Serra, Chief Scientific Officer, Neuroscience Technologies
16:10
Vesicular Glutamate Transporters (VGLUTs) as targets for neuropathic pain
Dr Gregor Bahrenberg, Associate Scientific Director, Grunenthal
16:50
Animal models and pain – what is new? : PANEL DISCUSSION
Anthony Jones, Professor of Neuro-Rheumatology, Human Pain Research Group, University of Manchester
16:50
Animal models and pain – what is new? : PANEL DISCUSSION
Jordi Serra, Chief Scientific Officer, Neuroscience Technologies
17:30
Chairman’s Closing Remarks and Close of Day One
Day 2
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Richard Knowles, CEO, Knowles Consulting
9:10
Placebo effects: mechanisms and translational aspects
Luana Colloca, Associate Professor, University of Maryland Baltimore, Baltimore, Special volunteer, National Institute of Mental Health (NIMH), NIH, Bethesda
9:50
Personalized medicine for pain, clinical validation with Nav1.7 blockers
Simon Tate, Chief Scientific Officer, Convergence Pharmaceuticals
10:30
Morning Coffee
10:50
Voltage gated sodium channels… perennial target for new pain therapies - are we making any progress
Richard Butt, Senior Director, Research Project Leader, Clinical Research, Pfizer
11:30
P2X-7 ATP-gated ion channels in chronic pain: more validation and more challenges
Emanuele Sher, Senior Research Advisor, Neuroscience Discovery, Lilly Research Centre, Eli Lilly
12:10
Networking Lunch
13:10
Kv1.2 as a platform to over-express members of the six-transmembrane segment family of ion channels for structural studies by demonstrating the overexpression of hERG
Shahnaz Yusaf, Investigator Biopharm Innovation BDU, GlaxoSmithKline
13:50
Update on Tanezumab, a monoclonal antibody inhibitor of nerve growth factor
Mark T Brown, MD, Executive Director, Tanezumab Clinical Program Leader for Osteoarthritis and Cancer Pain Studies, Pfizer
14:30
Afternoon Tea
14:50
Targeting NGF among the myriad pain mediators in chronic conditions
Steven Andrews, Director of Drug Discovey, Array BioPharma
15:30
CGRP receptor antagonists for the treatment of migraine
Ian Bell, Principal Scientist, Discovery Chemistry, Merck
16:10
P2X3 antagonism for treatment of pain, and sensitization-driven signs and symptoms of common diseases
Anthony Ford, Chief Scientific Officer, Afferent Pharmaceuticals, Inc.
16:50
Chairman’s Closing Remarks and Close of Day Two

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report